Franklin Biotechnology Discovery Adv (FTDZX)

Fund Assets	1.13B
Expense Ratio	0.741%
Min. Investment	$1,000
Turnover	37.62%
Dividend (ttm)	3.81
Dividend Yield	1.94%
Dividend Growth	n/a
Payout Frequency	Annual
Ex-Dividend Date	Dec 22, 2025

Previous Close	193.36
YTD Return	9.98%
1-Year Return	20.01%
5-Year Return	53.05%
52-Week Low	170.13
52-Week High	227.11
Beta (5Y)	0.92
Holdings	119
Inception Date	Sep 1, 2009

About FTDZX

Franklin Biotechnology Discovery Fund Advisor Class is a mutual fund that focuses on delivering capital appreciation by investing primarily in the biotechnology sector. Under normal market conditions, the fund allocates at least 80% of its net assets to equity securities of biotechnology companies and discovery research firms—enterprises that derive a significant portion of their revenue from biotechnology-related activities. The fund’s portfolio often includes both established and emerging biotechnology firms, with a notable allocation to smaller capitalization companies, typically those with market values below $2 billion at the time of investment. While the fund maintains a majority exposure to U.S.-based companies, it may allocate up to 20% of its assets to foreign securities, including American, European, and Global Depositary Receipts. Managed using a fundamental, research-driven investment approach, the fund seeks out companies with identifiable drivers of future earnings growth and sustainable growth characteristics. Franklin Biotechnology Discovery Fund Advisor Class plays a significant role in offering investors a specialized vehicle for gaining exposure to innovations and growth opportunities within the global biotechnology industry, reflecting both the sector’s risk profile and potential for long-term growth.

• Fund Family: Franklin Templeton
• Category: Health
• Performance Rating: Above Average
• Risk Rating: Above Average
• Stock Exchange: Nasdaq
• Ticker Symbol: FTDZX
• Share Class: Advisor Class
• Index: NASDAQ Biotechnology CR

Performance

FTDZX had a total return of 20.01% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.67%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FRBRX	Class R6	0.67%
FBDIX	Class A	1.01%
FBTDX	Class C	1.76%

Top 10 Holdings

36.65% of assets

Name	Symbol	Weight
Jazz Pharmaceuticals plc	JAZZ	5.06%
Amgen Inc.	AMGN	4.65%
argenx SE	ARGX	4.15%
Gilead Sciences, Inc.	GILD	4.11%
Vertex Pharmaceuticals Incorporated	VRTX	3.83%
Regeneron Pharmaceuticals, Inc.	REGN	3.74%
Revolution Medicines, Inc.	RVMD	3.13%
AstraZeneca PLC	AZN	2.72%
Ascendis Pharma A/S	ASND	2.68%
Amylyx Pharmaceuticals, Inc.	AMLX	2.57%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 22, 2025	$18.2306	Dec 22, 2025
Dec 20, 2024	$11.7607	Dec 20, 2024
Dec 20, 2022	$0.4163	Dec 20, 2022
Dec 15, 2021	$18.0843	Dec 15, 2021
Dec 15, 2020	$10.3921	Dec 15, 2020
Dec 16, 2019	$14.1643	Dec 18, 2019

Data Sources: Tiingo, Twelve Data, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Nov 4, 2026

Data Sources Report a data error